

Anti-4-1BB & CD40 Reference Antibody (Gen1042)

Catalog # APR11585

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q07011 & P25942
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	TNFRSF9 / 4-1BB / CD137,TNFRSF5 / CD40
Expression system	CHO

Protein Information

Images




Anti-4-1BB & CD40 Reference Antibody (Gen1042) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-4-1BB & CD40 Reference Antibody (Gen1042) is 96.80%, determined by SEC-HPLC.


Gen1042 bound to 4-1BB protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Gen1042 bound to hu-4-1BB-His, and the EC50 was 0.015 nM.




Gen1042 bound to CD40 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Gen1042 bound to hu-CD40-His, and the EC50 was 0.066 nM.




Gen1042 bound to hu4-1BB-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Gen1042 bound to hu4-1BB-CHO-K cells, and the EC50 was 4.119 nM.




Gen1042 bound to huCD40-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Gen1042 bound to huCD40-CHO-K cells, and the EC50 was 4.535 nM.



Co-incubation of Gen1042 with 4-1BB-NF-κB-Jurkat cells, then with the addition of huCD40-CHO-K cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Gen1042 was able to activate the NF-κB signaling pathway, and the EC50 was 0.234 nM.



The detected molecular weight of Anti-4-1BB & CD40 Reference Antibody (Gen1042) is 145.26 kDa.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.